Status:

COMPLETED

Role Of Ketamine in Treatment-Resistant Major Depressive Disorder And Its Effect on Suicidality

Lead Sponsor:

Assiut University

Conditions:

Treatment Resistant Depression

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

In this study we will assess the effect of Ketamine infusion on depressive symptoms and in particular its effect on Suicidal behavior, ideation and thoughts in patients with treatment- resistant MDD.

Detailed Description

A Twice repetition of IV infusion of 0.5 mg/kg of ketamine produces an antidepressant response in individuals with treatment-resistant MDD The work aims to: 1. To assess the onset of action and degr...

Eligibility Criteria

Inclusion

  • Patients fulfilling diagnostic criteria of treatment-resistant MDD.
  • Presence of suicidal risk.
  • No comorbid medical or neurological conditions.
  • Age above 18 years old.
  • Both gender.
  • Informed written consent from the patient or his legitimate.

Exclusion

  • Presence of perceptual disturbance.
  • History of sensitivity to ketamine.
  • Refusal to participate in the study.

Key Trial Info

Start Date :

September 1 2020

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

October 1 2021

Estimated Enrollment :

36 Patients enrolled

Trial Details

Trial ID

NCT04101474

Start Date

September 1 2020

End Date

October 1 2021

Last Update

March 5 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Assiut university

Asyut, Egypt